

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

Mark One

- QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Quarterly Period Ended June 30, 2007

OR

- TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission File Number 001-14053

MILESTONE SCIENTIFIC INC.

(Exact name of Registrant as specified in its charter)

Delaware

State or other jurisdiction or organization)

13-3545623

(I.R.S. Employer Identification No.)

220 South Orange Avenue, Livingston, New Jersey 07039

(Address of principal executive office)

(973) 535-2717

(Registrant's telephone number, including area code)

Check whether the Issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 14, 2007, the Issuer had a total of 11,724,516 shares of Common Stock, \$.001 par value, outstanding.

FORWARD LOOKING STATEMENTS

When used in this Quarterly Report on Form 10-QSB, the words “may”, “will”, “should”, “expect”, “believe”, “anticipate”, “continue”, “estimate”, “project”, “intend” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act regarding events, conditions and financial trends that may affect Milestone Scientific Inc.’s (“Milestone”)’s future plans of operations, business strategy, results of operations and financial condition. Milestone wishes to ensure that such statements are accompanied by meaningful cautionary statements pursuant to the safe harbor established in the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and that actual results may differ materially from those included within the forward-looking statements as a result of various factors. Such forward-looking statements should, therefore, be considered in light of various important factors, including those set forth herein and others set forth from time to time in Milestone’s reports and registration statements filed with the Securities and Exchange Commission (the “Commission”). Milestone disclaims any intent or obligation to update such forward-looking statements.

MILESTONE SCIENTIFIC INC.

I N D E X

	<u>PAGE</u>
PART I. FINANCIAL INFORMATION	
ITEM 1. Financial Statements (unaudited)	
<u>Condensed Balance Sheets June 30, 2007 (Unaudited) and December 31, 2006</u>	4
<u>Condensed Statements of Operations Three and Six Months Ended June 30, 2007 and 2006 (Unaudited)</u>	5
<u>Condensed Statements of Changes in Stockholders' Equity Six Months Ended June 30, 2007 (Unaudited)</u>	6
<u>Condensed Statements of Cash Flows Six Months Ended June 30, 2007 and 2006 (Unaudited)</u>	7
<u>Notes to Condensed Financial Statements</u>	8
ITEM 2. <u>Management's Discussion and Analysis or Plan of Operation</u>	13
ITEM 3 <u>Controls and Procedures</u>	18
PART II. <u>OTHER INFORMATION</u>	
<u>ITEM 6. Exhibits</u>	19
<u>SIGNATURES</u>	20
<u>CERTIFICATIONS</u>	21

MILESTONE SCIENTIFIC INC.
 CONDENSED BALANCE SHEETS

	June 30, 2007 (Unaudited)	December 31, 2006
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 192,527	\$ 1,160,116
Accounts receivable, net of allowance for doubtful accounts of \$79,612 in 2007 and \$16,519 in 2006	699,421	346,619
Royalty receivable	35,834	60,107
Inventories	1,566,027	1,323,338
Advances to contract manufacturer	1,149,121	1,077,871
Prepaid expenses	45,225	97,073
Total current assets	3,688,155	4,065,124
Investment in distributor, at cost	76,319	76,319
Equipment, net of accumulated depreciation of \$416,119 in 2007 and \$402,914 in 2006	432,765	459,259
Patents, net of accumulated amortization of \$53,362 in 2007 and \$41,938 in 2006	515,329	526,753
Other assets	12,261	14,153
Total assets	\$ 4,724,829	\$ 5,141,608
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities:		
Accounts payable	\$ 1,858,081	\$ 1,196,107
Accrued expenses	233,948	232,076
Deferred compensation payable to officers	75,000	
Total current liabilities	2,167,029	1,428,183
Stockholders' Equity		
Common stock, par value \$.001; authorized 50,000,000 shares; 11,757,849 shares issued, 337,036 shares to be issued, and 11,724,516 shares outstanding in 2007; 11,692,636 shares issued, 337,036 shares to be issued, and 11,659,303 shares outstanding in 2006	12,096	12,031
Additional paid-in capital	58,168,474	57,720,129
Accumulated deficit	(54,711,254)	(53,107,219)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total stockholders' equity	2,557,800	3,713,425
Total liabilities and stockholders' equity	\$ 4,724,829	\$ 5,141,608

See Notes to Condensed Financial Statements

[E/O] CRC: 41950
EDGAR 2

BNY Y38378 005.00.00.00 0/6


Queue: BNY_CPS
 Description: Form 10QSB

MILESTONE SCIENTIFIC INC.
 CONDENSED STATEMENTS OF OPERATIONS
 (Unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2007	June 30, 2006	June 30, 2007	June 30, 2006
Product sales, net	\$ 1,770,337	\$ 1,425,821	\$ 4,032,364	\$ 2,986,740
Royalty income	35,834	49,473	83,770	186,310
Total revenue	<u>1,806,171</u>	<u>1,475,294</u>	<u>4,116,134</u>	<u>3,173,050</u>
Cost of products sold	955,274	688,124	1,786,484	1,439,286
Royalty expense	(7,338)	5,637	(1,586)	22,057
Total cost of revenue	<u>947,936</u>	<u>693,761</u>	<u>1,784,898</u>	<u>1,461,343</u>
Gross profit	858,235	781,533	2,331,236	1,711,707
Selling, general and administrative expenses	1,809,554	1,369,497	3,646,442	2,849,212
Research and development expenses	121,398	390,741	299,964	554,183
Total operating expenses	<u>1,930,952</u>	<u>1,760,238</u>	<u>3,946,406</u>	<u>3,403,395</u>
Loss from operations	(1,072,717)	(978,705)	(1,615,170)	(1,691,688)
Interest income	3,799	24,690	11,135	52,094
Net loss	<u>\$ (1,068,918)</u>	<u>\$ (954,015)</u>	<u>\$ (1,604,035)</u>	<u>\$ (1,639,594)</u>
Loss per share — basic and diluted	<u>\$ (0.09)</u>	<u>\$ (0.08)</u>	<u>\$ (0.13)</u>	<u>\$ (0.14)</u>
Weighted average shares outstanding and to be issued - basic and diluted	<u>12,043,103</u>	<u>11,768,940</u>	<u>12,020,790</u>	<u>11,755,335</u>

See Notes to Condensed Financial Statements

[E/O] CRC: 55308
EDGAR 2

BNY Y38378 006.00.00.00 0/5


Queue: BNY_CPS
 Description: Form 10QSB

MILESTONE SCIENTIFIC INC.
 CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
 SIX MONTHS ENDED JUNE 30, 2007
 (Unaudited)

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Treasury Stock	Total
	Shares	Amount				
Balance, January 1, 2007	12,029,672	\$12,031	\$57,720,129	\$(53,107,219)	\$(911,516)	\$ 3,713,425
Common stock issued from exercise of stock options	46,667	47	54,554			54,601
Common stock and options issued for consulting services	—	—	251,702			251,702
Common stock and options issued for payment of employee compensation	18,546	18	142,089			142,107
Net loss				(1,604,035)		(1,604,035)
Balance, June 30, 2007	12,094,885	\$12,096	\$58,168,474	\$(54,711,254)	\$(911,516)	\$ 2,557,800

See Notes to Condensed Financial Statements

[E/O] CRC: 9513
EDGAR 2

BNY Y38378 007.00.00.00 0/2


Queue: BNY_CPS
 Description: Form 10QSB

MILESTONE SCIENTIFIC INC.
 CONDENSED STATEMENTS OF CASH FLOWS
 (Unaudited)

	SIX MONTHS ENDED JUNE 30,	
	2007	2006
Cash flows from operating activities:		
Net loss	\$(1,604,035)	\$(1,639,594)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation expense	50,262	48,661
Amortization of patents	11,424	11,424
Common stock and options issued for compensation and consulting	393,809	133,013
Bad debt expense (recovery)	64,378	(19,957)
Loss on disposal of equipment	—	1,918
Changes in operating assets and liabilities:		
Increase in accounts receivable	(417,180)	(137,372)
Decrease in royalty receivable	24,273	136,229
Decrease (increase) in inventories	(242,689)	85,583
Increase in advances to contract manufacturer	(71,250)	(96,448)
Decrease in prepaid expenses	51,848	23,774
Decrease in other assets	1,892	5,028
Increase in accounts payable	661,974	523,510
Increase (decrease) in accrued expenses	1,872	(45,501)
Increase in deferred compensation	75,000	108,332
Net cash used in operating activities	<u>(998,422)</u>	<u>(861,400)</u>
Cash flows from investing activities:		
Purchase of equipment	(23,768)	(10,716)
Payment for patent rights	—	(21,544)
Net cash used in investing activities	<u>(23,768)</u>	<u>(32,260)</u>
Cash flows from financing activities:		
Proceeds from exercise of stock options	54,601	—
Net cash provided by financing activities	<u>54,601</u>	<u>—</u>
NET DECREASE IN CASH AND CASH EQUIVALENTS	(967,589)	(893,660)
Cash and cash equivalents at beginning of period	<u>1,160,116</u>	<u>2,892,679</u>
Cash and cash equivalents at end of period	<u>\$ 192,527</u>	<u>\$ 1,999,019</u>

See Notes to Condensed Financial Statements

MILESTONE SCIENTIFIC INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)

Note 1 - Summary of accounting policies

The unaudited financial statements of Milestone have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

These unaudited financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2006 included in Milestone's Annual Report on Form 10-KSB. The accounting policies used in preparing these unaudited financial statements are the same as those described in the December 31, 2006 financial statements.

In the opinion of Milestone, the accompanying unaudited financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present Milestone's financial position as of June 30, 2007 and the results of its operations and cash flows for the three and six months ended June 30, 2007 and 2006.

The results reported for the three and six months ended June 30, 2007 are not necessarily indicative of the results of operations which may be expected for a full year.

The Company has incurred operating losses and negative cash flows from operating activities since its inception, including \$1,615,170 and \$998,422, respectively for the six months ended June 30, 2007. At June 30, 2007, the Company had cash and cash equivalents and working capital of \$192,527 and \$1,521,126, respectively. Additionally, as discussed in Note 11, on July 9, 2007, the Company secured a revolving line of credit in the aggregate amount of \$1,000,000 from a stockholder. The Company is actively pursuing generation of positive cash flows from operating activities through increases in revenues based upon management's assessment of present contracts and current negotiations and reductions in operating expenses. Subject to the achievement of the aforementioned increases in revenues and reductions in expenses, the Company believes that its current resources (including the line of credit) will be sufficient to fund its planned operations at least through June 30, 2008. However, if the Company is unable to generate positive cash flows from its operating activities it may need to raise additional capital. There is no assurance that the Company will be able to achieve positive operating cash flows or that additional capital, if required, can be raised on terms and conditions satisfactory to the Company if at all. If additional capital is required and it cannot be raised, then the Company could be forced to curtail medical product development activities, cut marketing expenses for existing dental products or adopt other cost saving measures, any of which might negatively affect the Company's operations.

Note 2- Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, distributor advance, cash flow assumptions regarding

MILESTONE SCIENTIFIC INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS (continued)
(Unaudited)

evaluations for impairment of long-lived assets and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

Note 3 - Royalty receivable

Royalty receivable represents the royalty due from United Systems Inc, the licensee of Milestone's proprietary consumer dental whitening product, which is sold under Milestone's distributor's trademark of *Ionic White*TM.

Note 4 - Inventories

Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market.

Note 5 - Advances to contract manufacturer

Advances to contract manufacturer represent deposits to the Company's contract manufacturer to fund future inventory purchases.

Note 6 - Basic and diluted net loss per common share

Milestone presents "basic" earnings (loss) per common share and, if applicable, "diluted" earnings per common share pursuant to the provisions of Statement of Financial Accounting Standards No. 128, "Earnings per Share" ("SFAS 128"). Basic earnings (loss) per common shares is calculated by dividing net income or loss by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is similar to that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants, and the conversion of notes payable and preferred stock were issued during the period.

Since Milestone had net losses for the three and six months ended June 30, 2007 and 2006, the assumed effects of the exercise of outstanding stock options and warrants were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options and warrants totaled 3,309,746 and 3,539,085 at June 30, 2007 and 2006, respectively.

Note 7 - Significant Customer

Milestone had one customer who accounted for approximately 88% and 69% of its net product sales for the three and six months ended June 30, 2007 and 22% of its net product sales for the three and six months ended June 30, 2006. Sales to customers outside the United States were 18% and 29% for the three months ended June 30, 2007 and 2006, respectively and were 18% and 31% for the six months ended June 30, 2006, respectively. At June 30, 2007, receivables from two customers were approximately 63% and 31% respectively of Milestone's gross accounts receivable.

Note 8 - Stock Option Plans

Milestone adopted Statement of Financial Accounting Standards No. 123(revised 2004), "*Share-Based Payment*, an Amendment of FASB Statement No. 123", (SFAS No. 123R) under the modified-prospective transition method on January 1, 2006. SFAS No. 123R requires all share-based payments to employees, including grants of employee stock

MILESTONE SCIENTIFIC INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS (Continued)
(Unaudited)

options, to be recognized in the income statements over the service period, as an operating expense, based on the grant-date fair values. Pro-forma disclosure is no longer an alternative. As a result of adopting SFAS No. 123R, the Company recognizes as compensation expense in its financial statements the unvested portion of existing options granted prior to the effective date and the cost of stock options granted to employees after the effective date based on the fair value of the stock options at grant date.

Employees: As of June 30, 2007, employees held 137,667 outstanding options granted to them under the Milestone 1997 Stock Option Plan and 305,000 outstanding options granted to them under the Milestone 2004 Stock Option Plan. In accordance with SFAS No. 123R the Company recognized \$76,653 and \$97,420 in share-based compensation expense for the three and six months ended June 30, 2007 respectively.

The fair value of each option granted was estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions used for grants in the six months ended June 30, 2007: dividend yield of 0%; expected volatility of 96%; risk free interest rate of 4.97% and expected term of 3.5 years.

Expected volatilities are based on historical volatility of the company's common stock. The company uses historical data to estimate option exercise and employee termination within the valuation model. The expected term of the option granted is estimated based on historical behavior of employees and represents the period of time that options granted are expected to be outstanding. A summary of option activity under the plan as of June 30, 2007, and changes during the six months then ended is presented below:

Options	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, January 1, 2007	427,834	\$ 1.85	3.34	—
Granted	80,000	1.68	—	—
Exercised	(46,667)	1.17	—	—
Forfeited or expired	(18,500)	3.40	—	—
Outstanding, June 30, 2007	442,667	\$ 1.83	3.36	\$306,551
Exercisable, June 30, 2007	329,000	\$ 1.96	3.16	\$221,434

As of June 30, 2007, there was \$84,276 of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the plan. That cost is expected to be recognized over a weighted average period of approximately one year.

Non-Employees: As of June 30, 2007, non-employees, including consultants, held 347,466 outstanding options granted to them under the Milestone 1997 Stock Option Plan and 291,667 outstanding options granted to them under the Milestone 2004 Stock Option Plan. The Company recognized a reduction of \$(1,236) and \$226,702 in share-based compensation expense for the

MILESTONE SCIENTIFIC INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS (Continued)
(Unaudited)

three and six months ended June 30, 2007 respectively.

The fair value of each option granted is estimated on the date of the grant and is thereafter revalued at each reporting date using the Black-Scholes option pricing model with the following assumptions used for the grants in the six months ended June 30, 2007: dividend yield of 0%; expected volatility of 123%; risk free interest rate of 4.58%; and expected term of 3 years.

Expected volatilities are based on historical volatility of the company's common stock. The expected term of the option granted is estimated based on historical behavior of nonemployees and represents the period of time that options granted are expected to be outstanding. A summary of option activity under the plan as of June 30, 2007, and changes during the six months then ended is presented below:

	Number of Options	Weighted average exercise price of options	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, January 1, 2007	522,466	\$ 3.51	3.17	—
Granted	125,000	1.75	—	—
Exercised	—	—	—	—
Forfeited or expired	(8,333)	4.92	—	—
Outstanding, June 30, 2007	639,133	\$ 3.15	3.06	\$ 81,999
Exercisable, June 30, 2007	461,355	\$ 3.47	2.58	\$ 10,611

As of June 30, 2007, there was \$203,743 of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the plan. That cost is expected to be recognized over a weighted average period of two years.

Note 9 – Agreements to Issue Common Stock and Stock Options

Under an agreement, the Company's marketing associate for a consumer tooth whitening product agreed to purchase, at \$3.00 per share, 500,000 shares of Milestone common stock in quarterly installments of 125,000 shares within 10 days after the end of each of the four fiscal quarters commencing July 1, 2005. Milestone is not required to sell these shares unless the associate has purchased at least 625,000 starter kits in the first quarter, at least 1,250,000 starter kits in the first two quarters and at least 1,875,000 starter kits in the first three quarters. Further, at Milestone's option, all shares previously purchased must be returned to Milestone and all monies paid to Milestone returned to the associate if it has not purchased an aggregate of at least 3,000,000 starter kits for the twelve-month period ending June 30, 2006.

This agreement has been repeatedly extended for the associate's commitment to purchase common stock. As of June 30, 2007, no shares have been sold under this agreement, as the associate did not purchase the minimum amount of starter kits.

MILESTONE SCIENTIFIC INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS (Continued)
(Unaudited)

Note 10- Recent Accounting pronouncements

In June 2006, the Financial Accounting Standards Board (FASB) issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109" (FIN 48). FIN 48 clarifies the accounting for uncertainties in income taxes recognized in a company's financial statements in accordance with Statement 109 and prescribes a recognition threshold and measurement attributable for financial disclosure of tax positions taken or expected to be taken on a tax return. Additionally, FIN 48 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. We adopted the provisions of FIN 48 as of January 1, 2007. The adoption of FIN 48 did not impact our financial position, results of operations or cash flows for the three and six months ended June 30, 2007.

In February 2007, the FASB issued FASB No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities Including an Amendment of FASB Statement No. 115," (FASB 159) which permits companies to measure many financial instruments and certain other assets and liabilities at fair value on an instrument-by-instrument basis (the fair value option). FASB 159 is effective for us on January 1, 2008. We are currently evaluating the possible impact of adopting FASB 159 on our consolidated financial statements.

In September 2006, the FASB issued FASB No.157, "Fair Value Measurements. (FASB 157)." FASB 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. FASB 157 is effective for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years. The Company does not expect adoption of FASB 157 to have material effect on its results of operations or financial position.

Note 11- Contingent Liabilities

Through December 31, 2006 Milestone paid royalties in connection with its tooth whitening products to a purported holder of patent rights therein. Late in 2006 it received a copy of a patent office filing which appeared to show that the purported owner had relinquished rights to the patent on which royalties had been paid. It is possible that, never-the-less, the purported owner may claim continuing rights to receive royalties or that others may claim that payments are owed in connection with Milestone's prior sales.

Note 12- Subsequent event, Line of credit

On July 9, 2007 we secured a \$1 million line of credit from a stockholder. Borrowings will bear interest at 6% per annum, with one year's interest at 1% payable in advance on each draw. Borrowings and subsequent repayments may be made from time to time, in increments of \$100,000, until the expiration date of the line on December 31, 2008. All borrowings and interest thereon must be repaid by June 30, 2010, and after the expiration date of the line, may be repaid by Milestone in cash or, at its option, in shares of Common Stock valued at the lower of \$2.00 per share or 80% of the average closing price of its shares during the 20 days ending with December 31, 2008. After December 31, 2008, and before June 30, 2010 the lender may convert all or any part of the then outstanding balance and interest thereon into shares of common stock at \$4.00 per share. Three year warrants, exercisable at \$5.00 per share, in an amount determined by dividing 50% of the amount borrowed by \$5.00, will be issued on each drawdown. There is no facility fee on the line.

ITEM 2. Management's Discussion and Analysis or Plan of Operation.

OVERVIEW

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this Form 10-QSB. This discussion may contain forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, such as those set forth in our Form 10-KSB for the year ended December 31, 2006.

During the first two quarters of 2007, the Company made considerable progress in advancing its refined business strategy primarily focused on the development, commercialization and global marketing and distribution of innovative painless injection products based on its patented technology, *CompuFlo*. Particular emphasis has been concentrated on bringing our patented and novel *Single Tooth Anesthesia (STA)* delivery system to market, which incorporates the "pressure force feedback" elements of the *CompuFlo* technology, allowing dental practitioners to accurately administer injections into the periodontal ligament space, thus effectively anesthetizing a single tooth.

In January 2007, Milestone finalized an Exclusive Distribution and Supply Agreement with Henry Schein, Inc., one of the world's largest medical and dental distribution companies, to become the exclusive distributor of the *STA* and *CompuDent* systems (and related ancillary products) in both North America and Canada. We also granted Henry Schein first right of refusal on distribution rights of the same products in the international marketplace, excluding Poland, Norway, Sweden, Denmark and South Africa, where we have already identified alternative sales and distribution partners.

In February 2007, the *STA* was formally unveiled to market at the 142nd Chicago Dental Society Midwinter Meeting, one of the largest dental trade events held each year in the U.S. In late March, we began fulfilling purchase orders from Henry Schein for the *STA*, with revenue recognition occurring upon shipment. This resulted in a material improvement in our domestic sales performance during the first and second quarters of this year, with the collective impact totaling \$1,187,352 in sales of *STA* systems and \$42,094 in sales of *STA* disposable handpieces. In addition, also in February 2007, Milestone received purchase orders in the amount of \$347,724 for *CompuDent* systems and handpieces.

The initial controlled soft introduction of our *STA* delivery system in the U.S. and Canada was designed to assess and affirm our planned sales, marketing and pricing strategies, as well as develop grass-roots support in the field prior to our full scale launch of the *STA* system scheduled to occur in the fourth quarter of this year or during the first quarter of 2008.

Shipments of the *STA* delivery system to Henry Schein's customers in the first and second quarters of 2007 should help to generate opportunities to promote much more rapid market adoption of the product by dental professionals following the full scale product launch. Further, early adopters of the *STA* System should prove to be valuable sources of insight and information regarding the powerful functionality and user benefits of the system, helping us to build a meaningful library of product testimonials and a solid base of professional references that will support and promote Henry Schein's sales and marketing efforts over time.

Through the third quarter 2007 and in collaboration with Corestrength, Inc., a leading professional dental sales management company contracted in late 2006, we will be engaged in extensive *STA* product training with Henry Schein's national sales force, in preparation of the national product launch. A significant acceleration of the *STA* market introduction is planned for the fourth quarter of 2007 beginning with the American Dental Association meeting in September. The acceleration activities

include special sales incentive programs, direct e-mail communications and other advertising/promotional programs.

Due to our reduced focus on supporting formal sales and marketing initiatives associated with our legacy dental injection system, *CompuDent*, domestic sales of the legacy product declined by 78% in the second quarter of 2007 to \$51,070 when compared to \$230,068 in the second quarter of the prior year. For the first six months of 2007, domestic sales of *CompuDent* decreased by 25% to \$338,296 from \$451,862 in the first six months of 2006. However, domestic sales of our disposable handpieces used in conjunction with *CompuDent* increased by 11% in the second quarter of 2007 to \$814,881 when compared to \$735,482 in the second quarter of 2006. Likewise, domestic sales of handpieces in the six months ended June 30, 2007 increased 13% to \$1,673,255, as compared to \$1,477,136 in the comparable 2006 period.

International sales, overall, have continued to decline in 2007 due largely to our foreign distributors' anticipation of the commercial availability of our new *STA* system, which has circumvented pro-active marketing of the *CompuDent* system primarily in the European markets. Specifically, during the second quarter of 2007, international sales of *CompuDent* decreased \$85,285 or 144% from \$59,378 in the prior year's second quarter. For the six months ended June 30, 2007, international sales of *CompuDent* decreased by 76% to \$70,121 from \$291,286 in the 2006 period. Although sales of our disposable handpieces used with the *CompuDent* system increased 6% on a comparative basis for the six months ended 2007 as compared to 2006 – \$587,534 in 2007 as compared to \$555,074 in 2006, sales for the three months ended June 30, 2007 decreased 5% to \$299,692 from \$315,585 in the comparable 2006 period.

In June 2006, we succeeded in being granted a CE Mark for the *STA* system, which will permit sales and marketing of the system in European Union (EU) countries. Although we are now engaged in determining our near term tactical approach to supporting a formal international market launch of the product in the fourth quarter of this year, we have already begun shipping *STA* units and the associated disposable handpieces to our foreign master distributor. Consequently, during the second quarter of 2007, we recognized \$20,774 for *STA* systems and \$12,986 for handpieces.

The following table shows a breakdown of our product sales (net), domestically and internationally, by product category, and the percentage of product sales (net) by each product category:

	Three Months Ended June 30,				Six Months Ended June 30,			
	2007		2006		2007		2006	
		%		%		%		%
DOMESTIC								
<i>CompuDent</i>	\$ 51,070	3.5	\$ 230,068	22.7	\$ 338,296	10.2	\$ 451,862	22.0
<i>STA Units</i>	555,043	38.4	—	—	1,187,352	35.9	—	—
Handpieces	814,881	56.4	735,482	72.5	1,673,255	50.5	1,477,136	72.1
STA Handpieces	6,111	0.4	—	—	42,094	1.3	—	—
Other	18,581	1.3	48,450	4.8	68,239	2.1	120,997	5.9
Total Domestic	\$1,445,686	100.0	\$1,014,000	100.0	\$3,309,236	100.0	\$2,049,995	100.0
INTERNATIONAL		%		%		%		%
<i>CompuDent</i>	\$ (25,907)	(8.0)	\$ 59,378	14.4	\$ 70,121	9.7	\$ 291,286	31.1
<i>STA Unit</i>	20,774	6.4	—	—	20,774	2.9	—	—
Handpieces	299,692	92.3	315,585	76.6	587,534	81.2	555,074	59.3
STA Handpieces	12,986	4.0	—	—	12,987	1.8	—	—
Other	17,106	5.3	36,858	9.0	31,712	4.4	90,385	9.6
Total International	\$ 324,651	100.0	\$ 411,821	100.0	\$ 723,128	100.0	\$ 936,745	100.0
DOMESTIC/INTERNATIONAL ANALYSIS		%		%		%		%
Domestic	\$1,445,686	81.7	\$1,014,000	71.1	\$3,309,236	82.1	\$2,049,995	68.6
International	324,651	18.3	411,821	28.9	723,128	17.9	936,745	31.4
Total Product Sales	\$1,770,337	100.0	\$1,425,821	100.0	\$4,032,364	100.0	\$2,986,740	100.0

Milestone will continue to reinforce and support our growing international sales and distribution channels. By doing so, we hope to materially expand our global market penetration of the professional medical and dental industries and drive broad brand awareness and appreciation for both our legacy and newly commercialized painless injection solutions.

In the first quarter of 2007, we signed a Collaboration Agreement with Carticept Medical, Inc., an Atlanta-based company developing and commercializing advanced medical device technology for the minimally-invasive treatment of cartilage damage and osteoarthritis. Milestone and Carticept have agreed to collaborate, at Carticept's cost, on the development of a specialized Injection System for the treatment of arthritic joints. The Injection System will use our patented *CompuFlo* technology to painlessly inject Carticept's proprietary products into the intra-articular joint space. Once Carticept is satisfied that the prototype meets predetermined performance benchmarks, then Carticept and Milestone will develop a professional version of the System suitable for commercialization and distribution to the professional medical markets.

The Carticept agreement represented a significant step forward in our efforts to pursue strategic partnerships and revenue sharing collaborations with companies who share our interest in leveraging *CompuFlo* to develop new, cutting edge solutions capable of addressing many of the more than 700 market applications identified in the independent research study we commissioned in 2006.

As we progress through 2007, we will continue to work towards identifying other strategic opportunities for joint development projects using *CompuFlo* as the impetus for new product development.

Summary of Significant Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to accounts receivable, inventories, stock-based compensation, and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.

Results of Operations

The following table sets forth, for the periods presented, statement of operations data as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results.

	Three months ended				Six months ended			
	June 30, 2007		June 30, 2006		June 30, 2007		June 30, 2006	
Product sales, net	\$ 1,770,337	98%	\$ 1,425,821	97%	\$ 4,032,364	98%	\$ 2,986,740	94%
Royalty income	35,834	2%	49,473	3%	83,770	2%	186,310	6%
Total revenue	1,806,171	100%	1,475,294	100%	4,116,134	100%	3,173,050	100%
Cost of products sold	955,274	53%	688,124	47%	1,786,484	43%	1,439,286	45%
Royalty expense	(7,338)	0%	5,637	0%	(1,586)	0%	22,057	1%
Total cost of revenue	947,936	52%	693,761	47%	1,784,898	43%	1,461,343	46%
Gross profit	858,235	48%	781,533	53%	2,331,236	57%	1,711,707	54%
Selling, general and administrative expenses	1,809,554	100%	1,369,497	93%	3,646,442	89%	2,849,212	90%
Research and development expenses	121,398	7%	390,741	26%	299,964	7%	554,183	17%
Total operating expenses	1,930,952	107%	1,760,238	119%	3,946,406	96%	3,403,395	107%
Loss from operations	\$(1,072,717)	-59%	\$ (978,705)	-66%	\$(1,615,170)	-39%	\$(1,691,688)	-53%

Three Months ended June 30, 2007 compared to three months ended June 30, 2006

Total revenues for the three months ended June 30, 2007 and 2006 were \$1,806,171 and \$1,475,294 respectively. The \$330,877 or 22.4% increase in total revenues is primarily related to STA unit and handpiece sales of \$594,914 which did not exist in this same period last year offset by a decrease in domestic sales of *CompuDent* units of \$178,998 or 77.8%. Disposable

handpiece sales increased \$79,399 or 10.8% domestically while international sales decreased \$15,893 or 5.0%. The amount of \$35,834 or 2.0% of total revenue is royalty income from granting United Systems Inc. a license to manufacture, market, and sublicense the *Ionic White* to the consumer market.

Cost of products sold for the three months ended June 30, 2007 and 2006 were \$955,274 and \$688,124, respectively. The \$267,150 or 38.8% increase is primarily attributable to write down of slow moving whitening inventory of \$50,535 and refurbished *CompuDent* units of \$90,478. The balance of the increase is due to additional cost of goods sold for the higher revenues previously discussed. For the three months ended June 30, 2007, Milestone generated a gross profit of \$858,235 or 48% as compared to a gross profit of \$781,533 or 53% for the same period in 2006.

Selling, general and administrative expenses for the three months ended June 30, 2007 and 2006 were \$1,809,554 and \$1,369,497, respectively. The \$440,057 or 32.1% increase is attributable primarily to an increase in marketing and media costs related to the domestic introduction of the STA delivery system of approximately \$181,000 which include costs related to advertising, trade show participation and on going sales training and support, and approximately \$233,000 increase in professional fees and a \$75,417 non-cash charge associated with the accounting for share based compensation expense.

Research and development expenses for the three months ended June 30, 2007 were \$121,398 and \$390,741, respectively. The decrease of \$269,343 or 68.9% is due to completion of the development of Milestone's STA delivery system.

Loss from operations for the three months ended June 30, 2007 and 2006 was \$1,072,717 and \$978,705, respectively. The \$94,012 or 9.6% increase in loss from operations is primarily the result of inventory write-downs and higher selling, general and administrative costs as described earlier.

Interest income of \$3,799 was earned in the three months ended June 30, 2007 compared to \$24,690 earned for the same period in 2006. The decrease of \$20,891 or 84% in interest income is the result of a decreased average cash balance.

For the reasons explained above, net loss for the three months ended June 30, 2007 was \$1,068,918 as compared to a net loss of \$954,015 for the same period in 2006. The \$114,903 or 12.0% increase in net loss is primarily a result of inventory write-downs and higher selling, general and administrative costs as described earlier.

Six months ended June 30, 2007 compared to the six months ended June 30, 2006

Total revenues for the six months ended June 30, 2007 and 2006 were \$4,116,134 and \$3,173,050 respectively. Total revenues increased by \$943,084 or 29.7%. Contributing to this increase was STA unit and handpiece sales of \$1,263,207 which did not exist in this same period last year offset by a decrease in domestic sales of *CompuDent* units of \$113,566 or 25.1%. Additionally, international revenue decreased \$221,165 or 75.9% as compared to the comparable 2006 period. Domestic disposable handpiece sales increased \$196,119 or 13.3% and international disposable handpiece sales increased \$32,460 or 5.8%. The amount of \$83,770 or 2.0% of total revenue is royalty income from granting United Systems Inc. a license to manufacture, market, and sublicense the *Ionic White* to the consumer market. Royalty income (net of royalty expenses) declined \$78,897 or 48.0% reflecting retail competition in this increasingly highly competitive market.

Gross profit for the six months ended June 30, 2007 and 2006 was \$2,331,236 or 56.6% and \$1,711,707 or 53.9%, respectively. Gross profit in the 2007 period was reduced \$141,013 because of a write down of whitening inventory of \$50,535 and *CompuFent* refurbished units of \$90,478. The gross profit increase was due principally to the increase in units sold due to the STA delivery system previously discussed.

Selling, general and administrative expenses for the six months ended June 30, 2007 and 2006 were \$3,646,442 and \$2,849,212 respectively. The increase of \$797,230 or 28.0% is primarily attributable to an increase of \$260,796 in the non-cash charge associated with share based compensation, as well as an increase of approximately \$71,000 in marketing costs associated to the preliminary domestic launch of the STA delivery system, professional fees of approximately \$165,000 over 2006 levels primarily the result of increased patent protection costs, and royalty expenses associated with the STA delivery system and STA handpieces which did not exist last year amounted to approximately \$113,000.

Research and development expenses for the six months ended June 30, 2007 and 2006 were \$299,964 and \$554,183, respectively. These costs are primarily associated with the development of our STA delivery system and continuing efforts on the *CompuFlo*TM technology.

Interest income of \$11,135 was earned for the six months ended June 30, 2007 compared to \$52,094 for the same period in 2006. The decrease of \$40,959 or 78.6% is the result of a decreased average cash balance.

For the reasons explained above, net loss for the six months ended June 30, 2007 decreased by \$35,559 or 2.2% over the net loss for the six month period ended June 30, 2006.

Liquidity and Capital Resources

Milestone incurred net losses of \$3,152,268, \$1,604,035, and \$1,639,594 and negative cash flows from operating activities of \$1,650,718, \$998,422 and \$861,400 during the year ended December 31, 2006, and the six months ended June 30, 2007 and 2006, respectively.

As of June 30, 2007, Milestone had cash and cash equivalents of \$192,527 and working capital of \$1,521,126.

The Company has incurred operating losses and negative cash flows from operating activities since its inception, including \$1,615,170 and \$998,422, respectively for the six months ended June 30, 2007. At June 30, 2007, the Company had cash and cash equivalents and working capital of \$192,527 and \$1,521,126, respectively. Additionally, as discussed in Note 11, on July 9, 2007, the Company secured a revolving line of credit in the aggregate amount of \$1,000,000 from a stockholder. The Company is actively pursuing generation of positive cash flows from operating activities through increases in revenues based upon management's assessment of present contracts and current negotiations and reductions in operating expenses. Subject to the achievement of the aforementioned increases in revenues and reductions in expenses, the Company believes that its current resources (including the line of credit) will be sufficient to fund its planned operations at least through June 30, 2008. However, if the Company is unable to generate positive cash flows from its operating activities it may need to raise additional capital. There is no assurance that the Company will be able to achieve positive operating cash flows or that additional capital, if required, can be raised on terms and conditions satisfactory to the Company is at all. If additional capital is required and it cannot be raised, then the Company could be forced to curtail medical product development activities, cut marketing expenses for existing dental products or adopt other cost saving measures, any of which might negatively affect the Company's operations.

for at least the next 12 months. However, if Milestone determines that it is in its best interests to increase funding for the development of various proposed medical products from its own resources, rather than relying on the advancement of development funds by existing or potential development partners, if development partners willing to fund certain development activities cannot be found or if cash flow from operations is less than now expected, Milestone may need to raise additional capital. No assurances can be given that additional capital, if required, can be raised on terms and conditions satisfactory to Milestone. If additional capital is required and it cannot be raised, then Milestone could be forced to curtail medical product development activities, cut marketing expenses for existing dental products or adopt other cost saving measures, any of which might negatively affect long-term growth prospects.

ITEM 3. CONTROLS AND PROCEDURES

- a) *Evaluation of Disclosure Controls and Procedures.* Milestone's management, with the participation of the Chief Executive Officer and the Chief Financial Officer, carried out an evaluation of the effectiveness of Milestone's "disclosure controls and procedures" (as defined in the Securities Exchange Act, Rule 13a-15(e) and 15d-15(e)). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that Milestone's disclosure controls and procedures were effective, as of the date of their evaluation, for purposes of recording, processing, summarizing and timely reporting material information required to be disclosed in reports filed by Milestone under the Securities Exchange Act of 1934.
- b) *Changes in Internal Control over Financial Reporting.* There were no changes in our internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, Milestone's internal control over fiscal reporting.

PART II

ITEM 6. EXHIBITS

The following exhibits are filed herewith:

- 31.1 Chief Executive Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Acting Chief Financial Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Chief Executive Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Acting Chief Financial Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MILESTONE SCIENTIFIC INC.

Registrant

/s/ Leonard Osser

Leonard Osser
Chairman and Chief Executive Officer

/s/ David Cohn

David Cohn
Acting Chief Financial Officer

Dated: August 14, 2007

Exhibit 31.1

CERTIFICATION

I, Leonard Osser, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Milestone Scientific Inc. (“the Registrant”).
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and
 - c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2007

/s/ Leonard Osser
Leonard Osser
Chairman and Chief Executive Officer

Exhibit 31.2

CERTIFICATION

I, David Cohn, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Milestone Scientific Inc. ("the Registrant").
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and
 - c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2007

/s/ David Cohn

David Cohn
Acting Chief Financial Officer

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Milestone Scientific Inc. on Form 10-QSB for the three and six months ending June 30, 2007 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Leonard Osser, Chief Executive Officer of Milestone, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone.

/s/ Leonard Osser
Leonard Osser
Chief Executive Officer
August 14, 2007

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Milestone Scientific Inc. on Form 10-QSB for the three and six months ending June 30, 2007 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, David Cohn, Chief Financial Officer of Milestone, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone.

/s/ David Cohn

David Cohn
Acting Chief Financial Officer
August 14, 2007

Queue: BNY_CPS

[E/O] CRC: 38227
EDGAR 2

BNY Y38378 100.00.00.00 0/3


SEC 1344
(2-2002)
Previous
versions
obsolete

Persons who potentially are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

OMB APPROVAL

OMB Number: 3235-0058
Expires: April 30, 2009
Estimated average burden
hours per response 2.50

SEC FILE NUMBER

CUSIP NUMBER

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 12b-25

Commission File Number 001-14053

NOTIFICATION OF LATE FILING

(Check One):

- | | | |
|---|-------------------------------------|------------------------------------|
| <input type="checkbox"/> Form 10-K | <input type="checkbox"/> Form 20-F | <input type="checkbox"/> Form 11-K |
| <input checked="" type="checkbox"/> Form 10-Q | <input type="checkbox"/> Form 10-D | |
| <input type="checkbox"/> Form N-SAR | <input type="checkbox"/> Form N-CSR | |

For Period Ended: June 30, 2007

- | | |
|---|--|
| <input type="checkbox"/> Transition Report on Form 10-K | <input type="checkbox"/> Transition Report on Form 10-Q |
| <input type="checkbox"/> Transition Report on Form 20-F | <input type="checkbox"/> Transition Report on Form N-SAR |
| <input type="checkbox"/> Transition Report on Form 11-K | |

For the Transition Period Ended:

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A

Queue: BNY_CPS

[E/O] CRC: 38227
EDGAR 2

BNY Y38378 100.00.00.00-1 0/3


PART I — REGISTRANT INFORMATION

Milestone Scientific Inc.

Full Name of Registrant

Not Applicable

Former Name if Applicable

220 South Orange Avenue, Livingston Corporate Park

Address of Principal Executive Office (*Street and Number*)

Livingston, NJ 07039

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 11-K, 20-F, 10-Q, 10-D, N-SAR, N-CSR or the transition report or portion thereof, could not be filed within the prescribed time period.

The registrant is seeking additional advice from its lawyers as to the necessity, if any, for disclosing a potential contingent liability. As a result, the registrant was not able to file its quarterly report by August 14, 2007 without unreasonable effort or expense. The registrant believes that the quarterly report on Form 10-QSB for such period will be available for filing on or before August 20, 2007.